Mint highlights five pharma CDMO stocks with strong Q2FY27 growth
In short
Mint highlighted five pharma CDMO stocks with strong revenue growth in Q2FY27.
The note says rising revenues and more business opportunities are behind the interest in these companies.
What the reporting says
Mint highlighted five pharma CDMO stocks showing robust revenue growth in Q2FY27.
Why it matters
Mint’s market brief points to five pharma CDMO stocks as having strong revenue growth in Q2FY27. The summary ties the theme to rising revenues and expanding opportunities, but gives no names or numbers. The likely market relevance is to pharma manufacturing and outsourcing companies, though the available evidence is only a broad screening note.